241 related articles for article (PubMed ID: 35115827)
1. Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment.
Anaka M; Abdel-Rahman O
Cancer Manag Res; 2022; 14():273-285. PubMed ID: 35115827
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-induced cardiotoxicity: case report and review of the literature.
Ang C; Kornbluth M; Thirlwell MP; Rajan RD
Curr Oncol; 2010 Feb; 17(1):59-63. PubMed ID: 20179805
[TBL] [Abstract][Full Text] [Related]
3. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine cardiotoxicity--case reports and literature review.
Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):58-63. PubMed ID: 30470591
[TBL] [Abstract][Full Text] [Related]
7. Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress.
Kim HJ; Han YS; Lee JH; Lee SH
Anticancer Res; 2020 Mar; 40(3):1419-1426. PubMed ID: 32132038
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study.
Shimizu T; Murata S; Sonoda H; Mekata E; Ohta H; Takebayashi K; Miyake T; Tani T
Mol Clin Oncol; 2014 May; 2(3):399-404. PubMed ID: 24772307
[TBL] [Abstract][Full Text] [Related]
9. Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable?
Chakwop Ngassa H; Elmenawi KA; Anil V; Gosal H; Kaur H; Mohammed L
Cureus; 2021 Sep; 13(9):e17712. PubMed ID: 34650886
[TBL] [Abstract][Full Text] [Related]
10. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study.
Tsavaris N; Kosmas C; Vadiaka M; Skopelitis E; Kopteridis P; Pamouki S; Efremidis M; Kasparian H; Moisakis I; Sakelariou D; Koufos C
J BUON; 2005; 10(2):205-11. PubMed ID: 17343330
[TBL] [Abstract][Full Text] [Related]
12. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
[TBL] [Abstract][Full Text] [Related]
14. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
16. TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
Petrelli F; Barni S; Bertocchi P; Zaniboni A
BMC Cancer; 2016 Jul; 16():386. PubMed ID: 27377645
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
18. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
19. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
[TBL] [Abstract][Full Text] [Related]
20. Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.
Peters GJ; Smid K; Meijer E; van Groeningen CJ; Leon LG
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):595-603. PubMed ID: 27906628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
